Influence of soluble CD26 to the improvement of blood glucose by Dipeptidyl peptidase-4 inhibitory drugs

Not Applicable

• Conditions: type 2 diabetes

• Registration Number: JPRN-UMIN000008804
• Lead Sponsor: Department of Diabetes, Endocrinology and Metabolism, Kawasaki medical scool

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-08-30
• Study Completion: 2014-08-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Not provided

Exclusion Criteria

1. The patient who taking thiazolidinedione 2. The patient who taking insulin, or the absolute adaptation of insulin therapy 3. The patient who has renal dysfunction (Serum creatinine: male 1.5mg/dl<=, female 1.3mg/dl<=) 4. The patient who has liver dysfunction (ALT and AST: more than two times the upper limit of normal) 5. The patient who has endocrine disease 6. The patient who taking steroid 7. The patient who has malignacy 8. The patient who has severe psychiatric disease 9. The patient under pregnancy or lactation 10. The excessive alcohol ingestion 11. The contraindication of the drugs

Study & Design

• Study Type: Interventional
• Study Design: Not specified